Abbott Laboratories (ABT)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$95.09-0.78%
Close 2026-07-08 · 1-day change
Reading ABT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABT free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading ABT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABT free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on organic sales growth and EPS growth despite acquisition impacts. The current thesis state is stable, supported by strong recent financial performance.
The market appears to have priced in a neutral valuation compared to peers, with a slight premium. There is an expectations gap, indicating that the market may not fully recognize potential upside from ongoing growth initiatives.
Fundamentals are likely to continue showing strength, as management is on track with their growth targets. However, there is a moderate risk of missing earnings due to the high-miss-rate nature of the industry.
The thesis hinges on the performance of sector bellwethers like SYK, MDT, and BSX. Positive earnings and guidance from these companies could support ABT's growth, while any negative signals could pose risks.
Overall, ABT's position is solid, but it remains sensitive to sector dynamics and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Abbott cleared a major legal risk with the DOJ. However, it now faces a lawsuit over PediaSure, which could hurt its brand.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the court approves, it could end lawsuits and help Abbott's management. This might make investors more confident.
Confirms:The court approves the proposed settlement during the hearing on June 4, 2026.
Disproves:The court rejects the settlement or delays the decision beyond June 4, 2026.
Why it matters: Good integration and benefits could help Abbott grow in cancer tests.
Confirms:Management says they have saved at least $50 million a year from the purchase.
Disproves:Management says there are delays or problems with getting benefits from the purchase.
Why it matters: Guidance for Q2 adjusted EPS will show how well Abbott is handling acquisition effects.
Confirms one read:Q2 adjusted EPS guidance is raised above $1.31.
Confirms the other:Q2 adjusted EPS guidance is lowered below $1.25.
Why it matters: Guidance will show how well Abbott is handling the Exact Sciences deal's impact on earnings.
Confirms one read:Abbott projects Q2 2026 adjusted diluted EPS of $1.25 to $1.31.
Confirms the other:Abbott cuts Q2 2026 adjusted diluted EPS guidance to under $1.25.
Why it matters: Changes in sales growth guidance can show how well Abbott is doing in a tough market.
Confirms one read:Abbott raises its full-year 2026 sales growth guidance to above 7.5%.
Confirms the other:Abbott lowers its full-year 2026 sales growth guidance to below 6.5%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.